Maryland Medicaid: Cell and gene therapy covered for sickle cell disease
Starting Jan. 1, 2026, Maryland Medicaid offers coverage for FDA-approved cell and gene therapies for sickle cell disease through the Cell and Gene Therapy (CGT) Access Model. The program allows eligible Medicaid enrollees access to evaluation, apheresis, infusion, recovery and long-term follow-up at authorized treatment centers. Medicaid covers the following drugs therapies through the program:
- Casgevy
- Lyfgenia
What you can do
Discuss cell and gene therapy with UnitedHealthcare Community Plan members diagnosed with sickle cell disease and refer them for evaluation, as appropriate.
Resources
For clinical information and eligibility criteria, go to Maryland Department of Health: Medicaid Cell and Gene Therapy.
Questions? We're here to help.
Connect with us through chat 24/7 in the UnitedHealthcare Provider Portal.
PCA-1-25-02773-C&S-NN_01132026
